NCT02262026

The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism

A Phase One Study Investigating the Tolerability and Effects of AZD0530 on Functional Neuroimaging Responses in Individuals With or Without a Family History of Alcoholism

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

Functional neuroimaging of alcoholism vulnerability: glutamate, reward, impulsivity, and Pavlovian-to-instrumental transfer (PIT), part II Saracatinib

Detailed description

To assess the effect of oral AZ D0530 at various doses on neuroimaging parameters associated with various forms of impulsivity mediated through glutamate-dopamine interactions, as ascertained through functional magnetic resonance imaging. -- --NOTE-- AZD0530 dosage of 50mg was discontinued by manufacturer. Adjustments were made to account for the removal of the 50mg dosage in all arms of the study.

Conditions

• Alcoholism

Interventions

Type	Name	Description
DRUG	125 mg AZD0530	Randomized to receive 125 mg of AZD0530
DRUG	50 mg AZD0530	Randomized to receive 50 mg of AZD0530
DRUG	Placebo	Placebo

Timeline

• Start date: 2014-11-01
• Primary completion: 2019-04-26
• Completion: 2019-04-26
• First posted: 2014-10-10
• Last updated: 2023-02-24

Locations

1 site across 1 country: United States